18
Mar
2008
CLSDF continues to cover Cambridge-based Archemix; find out why (here) and (here). The aptamer company announced initiation of a Phase II study of ARC1779. The trial is designed to evaluate the safety and efficacy of ARC1779 as a first-in-class anti-platelet agent in patients suffering from a rare, life-threatening blood disorder known as thrombotic thrombocytopenic purpura [...]
17
Mar
2008
On the lookout for some news whilst perusing the 100+ page Form 10-K annual report filed by Replidyne (NASDAQ: RDYN) with the SEC on Friday I found the information provided on the regulatory process to be just a fantastic overview. So with some minor tweaks and a sincere appreciation to the folks in Louisville what [...]
14
Mar
2008
At the recent year-end call Allos Therapeutics (NASDAQ: ALTH) reported financial and developmental 2007 highlights. As-of 31 December the company had a cash and cash equivalent position of $57.8M on hand, the coffers were achieved primarily via a 1Q07 9M common share offering that raised just north of $50M. With a quarterly burn of approximately [...]
12
Mar
2008
Get those bio biz plans submitted ASAP to the 7th Annual Bard Center Business Plan Competition. The Bard competition accepts plans from students, alumni, and faculty from ALL higher education institutions and graduate programs in Colorado. So let’s see Ft. Collins and Colorado Springs get into the mix! The goals of the competition are to [...]
12
Mar
2008
Most recently Amgen (NASDAQ: AMGN) announced the second successful Phase III trial for Denosumab (manufactured in Longmont, CO) osteoporosis study, which met all of its primary and secondary bone mineral density (BMD) endpoints in a head-to-head comparison with Merck’s (NYSE: MRK) Fosamax® in post menopausal women. Back in December of ‘07 CLSDF set the Amgen-Denosumab [...]
11
Mar
2008
What do you get when combing Colorado-based Nobel Laureate technology (Dr. John Hall, 2005-Physics) with Colorado-based All-Star management (Dr. Bill Freytag, Chair & CEO Aspreva Pharma, Chair & CEO Myogen)? Answer…alphsniffer…who announced the appointment of Dr. J. William Freytag as the new Chairman of the Board of Directors. Congratulations to Founder and CEO Misha Plam, [...]
10
Mar
2008
You know a deal is done when one goes to the Pharmion.com website and the Celgene (NASDAQ: CELG) site pulls up. Last Thursday Pharmion shareholders approved the acquisition and by Friday it was signed, sealed and delivered…$2.9B later or $25 in cash plus 0.8367 shares of Celgene for each share of Pharmion. Congratulations to both [...]
10
Mar
2008
CLSDF: Subscriber Growth Update
Posted in My Rants
I like to announce every time CLSDF adds another 100 subscribers; the blog is now north of 400. Infinite appreciation to all of you for subscribing, your feedback (positive and negative) is treasured and motivating. If you find CLSDF to be of continuing value than I ask that you inform your friends and colleagues about [...]
07
Mar
2008
The pros from PureTech Ventures (Boston), Accelerator Corp (Seattle) and BioAdvance (Philadelphia) spent some time yesterday setting the table of today’s current early-stage biotech investing climate and proceeded to illuminate some absolutely critical elements to incorporate while on the fund-raising trail. Without a doubt the present day funding gap or ‘valley of death’ is real [...]
06
Mar
2008
Norm Pace, Ph.D. of CU Molecular, Cell and Developmental Biology was honored by the CU Board of Regents with the distinction of Distinguished Professor. Dr. Pace can now add this title to his impressive list of accomplishments which include member of the National Academy of Sciences and the American Academy of Microbiology, as well as [...]
05
Mar
2008
Great news from Array Biopharma (NASDAQ: ARRY) re: Phase II results from the ARRY-797 asset, a small molecule p38-alpha inhibitor which modulates the production of TNF, IL-1 and IL-6 inflammatory mediators and the PGE2 pain mediator. The post-surgical molar extraction dental pain study achieved all of its total pain relief endpoints for analgesic efficacy. ARRY-797 [...]
05
Mar
2008
For the first time in years, say since undergrad, I sat down and consumed an entire book, cover-to-cover in a single sitting. It was Valley Boy: The Education of Tom Perkins that sucked me in on a snowy Sunday. Tom Perkins helped to pioneer the innovation center that is Silicon Valley, first at Hewlett Packard [...]
04
Mar
2008
And the BioBeers beat marches on in March at the Milwaukee Street Tavern. Do you speak Cherry Creek? That’s right the Colorado BioBeers tour continues, pulling in next to the Milwaukee Street Tavern Station, 31 March 7:30pm. This month we are including FREE name tags! Bonus! And suitable for framing too after the event. It [...]
Life Science Deal Flow PARTNERS
-
